Abstract

Despite 25 years of ADHD pharmacogenetic studies, there are few reliable predictors to guide treatment. The dopamine transporter (DAT1) is a primary pharmacodynamic target for methylphenidate (MPH) with known genetic variation hypothesized to impact response, while CYP2D6 variation impacts atomoxetine (ATX) kinetics. We examined genetic variation in DAT1 and CYP2D6 with dose response in youth diagnosed with ADHD exposed to both medications.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call